Chase Therapeutics Corp — Form D
Chase Therapeutics Corp of WASHINGTON, DC, a company, filed a Form D exempt-offering notice with the SEC on 2017-11-29. The offering totals $1.3M, of which $1.3M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2017-11-29
- Form: D
- Accession: 0001723805-17-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $1.3M
- Amount sold: $1.3M
- Minimum investment: $1
- Investors: 1
- Date of first sale: 2017-11-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-299627
Issuer
- Name: Chase Therapeutics Corp
- CIK: 0001723805
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 1825 K STREET NW, WASHINGTON, DC, 20006
- Phone: 202-223-7002
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Richard P Dulik | Executive Officer | Washington, DC |
| Kathleen N Clarence-Smith | Director | Washington, DC |
| Karoly P Nikolich | Director | Washington, DC |
| John P Reher | Director | Washington, DC |
| Thomas N Chase | Director | Washington, DC |
| Thomas N Chase | Executive Officer | Washington, DC |
Other filings by this issuer (1)
More